All In Biotech

NDA 017871 · Bausch

Demser

Metyrosine · Oral · Catecholamine Synthesis Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jul 15, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Oct 3, 1979

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

1 Phase 3, 0 recruiting

FAERS reports

81

69 serious, 21 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2021.

INDICATIONS AND USAGE DEMSER is indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery 2. Management of patients when surgery is contraindicated 3. Chronic treatment of patients with malignant pheochromocytoma DEMSER is not recommended for the control of essential hypertension.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 3, 1979 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • DEMSER · METYROSINE 250MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Metyrosine" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use16
  • somnolence12
  • pneumonia7
  • diarrhoea6
  • pyrexia6
  • drug ineffective5
  • hospitalisation5
  • malaise5
  • phaeochromocytoma4
  • vomiting4
  • blood pressure increased3
  • constipation3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20091
20101
20121
20131
20152
20164
20176
20181
20194
20205
20219
20226
202313
20244
202516
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Demser (Metyrosine)

2024 spending

$233K

Beneficiaries

n/a

13 claims

Per beneficiary

n/a

$406.92 per unit

View as table
YearSpending
2020$3,068,803
2021$1,090,580
2022$225,809
2023$320,548
2024$233,163

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 12 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.